Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) and Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, earnings, dividends, analyst recommendations, institutional ownership and valuation. Profitability This table compares Fulcrum Therapeutics and Vertex […]
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) CEO Dipal Doshi sold 1,000 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $15.99, for a total transaction of $15,990.00. Following the completion of the transaction, the chief executive officer now directly […]
- With a proven track record at Entrada and across his 30-year career in the healthcare sector, Mr. Dowden is well-positioned to help continue driving.
Kory Wentworth, the CFO of Entrada Therapeutics Inc (NASDAQ:TRDA), executed a sale of 12,500 shares in the company on December 26, 2023, according to a recent SEC Filing.